ATE322249T1 - System zur abgabe einer tobramycin-formulierung - Google Patents

System zur abgabe einer tobramycin-formulierung

Info

Publication number
ATE322249T1
ATE322249T1 AT02771857T AT02771857T ATE322249T1 AT E322249 T1 ATE322249 T1 AT E322249T1 AT 02771857 T AT02771857 T AT 02771857T AT 02771857 T AT02771857 T AT 02771857T AT E322249 T1 ATE322249 T1 AT E322249T1
Authority
AT
Austria
Prior art keywords
delivery system
formulation delivery
tobramycin
less
tobramycin formulation
Prior art date
Application number
AT02771857T
Other languages
German (de)
English (en)
Inventor
Robert J Speirs
Barbara A Schaeffler
Peter B Challoner
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23123791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE322249(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE322249T1 publication Critical patent/ATE322249T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT02771857T 2001-05-18 2002-05-17 System zur abgabe einer tobramycin-formulierung ATE322249T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29223401P 2001-05-18 2001-05-18

Publications (1)

Publication Number Publication Date
ATE322249T1 true ATE322249T1 (de) 2006-04-15

Family

ID=23123791

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02771857T ATE322249T1 (de) 2001-05-18 2002-05-17 System zur abgabe einer tobramycin-formulierung

Country Status (11)

Country Link
US (8) US20030143162A1 (https=)
EP (2) EP1320355B1 (https=)
JP (2) JP2004534763A (https=)
AT (1) ATE322249T1 (https=)
AU (1) AU2010210026A1 (https=)
CA (1) CA2447600C (https=)
DE (1) DE60210402T2 (https=)
DK (1) DK1320355T3 (https=)
ES (1) ES2261735T3 (https=)
PT (1) PT1320355E (https=)
WO (1) WO2002094217A1 (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
US20030143162A1 (en) 2001-05-18 2003-07-31 Speirs Robert John Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US20040022740A1 (en) * 2001-07-10 2004-02-05 Baker William R. Macrolide formulations for inhalation and methods of treatment of endobronchial infections
CA2456746A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
US8245708B2 (en) * 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
EP1545459A4 (en) * 2002-08-02 2007-08-22 Transave Inc PLATINUM AGGREGATES, AND METHOD FOR MANUFACTURING THE SAME
AU2002953095A0 (en) * 2002-11-29 2002-12-19 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
EP1638549A4 (en) * 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
NZ546821A (en) * 2003-10-15 2009-04-30 Pari Pharma Gmbh Liquid preparation containing tobramycin
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
CA2559722A1 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
ES2388420T3 (es) * 2004-05-17 2012-10-15 Gilead Sciences, Inc. Combinación de fosfomicina/aminoglucósido aerosolizada para el tratamiento de las infecciones respiratorias bacterianas
WO2005112957A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
WO2006002178A1 (en) 2004-06-18 2006-01-05 Novartis Vaccines And Diagnostics Inc. Methods of treatment of endobronchial infections
MX2007004955A (es) * 2004-11-08 2007-06-14 Transave Inc Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
WO2007041156A2 (en) * 2005-09-29 2007-04-12 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
AU2013206401B2 (en) * 2005-09-29 2016-06-23 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056263A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190181A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
WO2007064658A2 (en) * 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
EP3067047B1 (en) 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US8337814B2 (en) * 2005-12-15 2012-12-25 Topical Sinus Therapeutics, Inc. Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions
JP2008199905A (ja) * 2007-02-16 2008-09-04 Snow Brand Milk Prod Co Ltd 乳酸菌生残性向上剤
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
CN101981688B (zh) * 2008-04-02 2014-04-02 Imec公司 制造半导体器件的方法以及半导体器件
JP5711135B2 (ja) 2008-10-24 2015-04-30 センプラ ファーマシューティカルズ，インコーポレイテッド 胃腸疾患を治療するための方法
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2608285T3 (es) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
MX361413B (es) 2010-03-22 2018-12-05 Cempra Pharmaceuticals Inc Star Formas cristalinas de un macrólido y usos para las mismas.
CN102917708B (zh) 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
KR102012418B1 (ko) * 2010-07-12 2019-08-20 셀리아 파마슈티칼즈 에이피에스 에어로졸화에 의한 토브라마이신의 투여에 의한 폐 감염의 치료
EP2613630A4 (en) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
KR20140025534A (ko) 2011-07-12 2014-03-04 카르데아스 파마 인코퍼레이티드 아미카신과 포스포마이신 조합물의 제형 및 인공호흡기 관련 폐렴(vap)과 인공호흡기 관련 기도(vat) 기관지염의 치료 방법 및 시스템
NZ700182A (en) 2012-03-27 2017-02-24 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
GB201208080D0 (en) 2012-05-09 2012-06-20 Norton Healthcare Ltd Tobramycin formulation
DK2892524T3 (da) 2012-09-04 2021-01-25 Eleison Pharmaceuticals LLC Forebyggelse af pulmonalt kræfttilbagefald med lipid-komplekseret cisplatin
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
EP2943503B1 (en) 2013-01-11 2017-08-23 Xellia Pharmaceuticals ApS Polymyxins, compositions, methods of making and methods of use
AU2014239959A1 (en) * 2013-03-14 2015-10-01 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
CN105188712A (zh) 2013-03-15 2015-12-23 森普拉制药公司 用于制备大环内酯抗菌剂的收敛方法
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
EP3166960B1 (en) 2014-07-09 2019-08-07 Xellia Pharmaceuticals ApS Low substituted polymyxins and compositions thereof
US10532080B2 (en) 2014-10-03 2020-01-14 Xellia Pharmaceuticals Aps Sulfomethylated polymixin compositions
JP6626890B2 (ja) 2014-10-03 2019-12-25 クセリア ファーマシューティカルズ エーピーエスＸｅｌｌｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＡｐＳ 吸入用デバイスおよび同デバイスに含有される水溶液
US10617703B2 (en) 2014-12-10 2020-04-14 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10898491B2 (en) 2015-12-18 2021-01-26 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11690815B2 (en) 2015-08-05 2023-07-04 Cmpd Licensing Llc Hyperkeratotic skin condition treatments and compositions
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11278590B2 (en) 2015-08-05 2022-03-22 Cmpd Licensing, Llc Compositions and methods for treating nail infections
US10898455B2 (en) 2016-01-07 2021-01-26 Cmpd Licensing, Llc Urea cream formulations
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
JP7449275B2 (ja) 2018-05-02 2024-03-13 インスメッド インコーポレイテッド リポソーム薬物製剤の製造方法
WO2020163416A1 (en) * 2019-02-05 2020-08-13 Mylan Inc Devices and methods for tobramycin inhalation treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993223A (en) 1974-07-25 1976-11-23 American Home Products Corporation Dispensing container
US4502616A (en) 1982-01-04 1985-03-05 Health Care Concepts, Inc. Single use vial
GB8801655D0 (en) 1988-01-26 1988-02-24 Waverley Pharma Ltd Ampoules
ES2038445T3 (es) 1988-01-28 1993-07-16 Lameplast S.R.L. Tiras de ampollas para productos farmaceuticos, cosmeticos y otros.
GB8802349D0 (en) 1988-02-03 1988-03-02 Waverley Pharma Ltd Ampoule with luer
DE3916840A1 (de) 1988-09-21 1990-03-29 Bernd Hansen Ampulle
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
CA2027690A1 (en) 1990-10-18 1992-04-19 Christian Laing Plastic ampul
FR2687066A1 (fr) 1992-02-06 1993-08-13 Oreal Ampoule autocassable.
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5758637A (en) * 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US6387886B1 (en) 1998-12-17 2002-05-14 Chiron Corporation Method for the treatment of severe chronic bronchitis (bronchietasis) with an aerosolized antibiotic
SE9902627D0 (sv) * 1999-07-08 1999-07-08 Siemens Elema Ab Medical nebulizer
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US20030143162A1 (en) 2001-05-18 2003-07-31 Speirs Robert John Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics

Also Published As

Publication number Publication date
DE60210402T2 (de) 2006-12-07
US7825095B2 (en) 2010-11-02
EP1320355A1 (en) 2003-06-25
US6890907B2 (en) 2005-05-10
EP2186508A2 (en) 2010-05-19
US8507454B2 (en) 2013-08-13
US20110005518A1 (en) 2011-01-13
US20120101055A1 (en) 2012-04-26
US20040131555A1 (en) 2004-07-08
PT1320355E (pt) 2006-08-31
JP2004534763A (ja) 2004-11-18
US20050201947A1 (en) 2005-09-15
CA2447600A1 (en) 2002-11-28
WO2002094217A1 (en) 2002-11-28
EP1320355B1 (en) 2006-04-05
DK1320355T3 (da) 2006-07-31
EP2186508A3 (en) 2010-08-25
DE60210402D1 (de) 2006-05-18
JP2009269923A (ja) 2009-11-19
US20050207987A1 (en) 2005-09-22
US20040265241A1 (en) 2004-12-30
US20030143162A1 (en) 2003-07-31
AU2010210026A1 (en) 2010-09-02
ES2261735T3 (es) 2006-11-16
US20080095717A1 (en) 2008-04-24
CA2447600C (en) 2015-10-20

Similar Documents

Publication Publication Date Title
ATE322249T1 (de) System zur abgabe einer tobramycin-formulierung
WO2002043750A3 (en) Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
NZ552047A (en) Method of treatment of endobronchial infections
IL139230A0 (en) Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds to the upper respiratory tract and/or the ear
BR0109875A (pt) Tratamento de doenças respiratórias
EP0861667A3 (en) Particulate agents
WO2001064182A3 (en) Improvements in or relating to the delivery of oral drugs
GB9814172D0 (en) Formulation for inhalation
IL101056A (en) Composition for nasal treatment
MXPA03000353A (es) Medicamentos para tratamiento quimioterapeutico de enfermedades.
MY144021A (en) Pharmaceutical delivery system
WO2002003998A3 (en) Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU644094B2 (en) Medicaments
MXPA05009629A (es) Composiciones que contienen trospio.
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
DK98089D0 (da) Medikament-lipid-systemer med lav toxicitet
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
CA2564546A1 (en) Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
DK1673074T3 (da) Flydende præparat, indeholdende tobramycin
NO20041011L (no) Inhaleringssammensetninger omfattende tricykliske 5,6-dihydro-9H-pyrazolo(3,4-C) -1,2,4-triazolo(4,3-alfa)pyridiner
AU2615795A (en) Compounds and compositions for administration via oral inhalation or insufflation
KR20090042507A (ko) 돼지 위축성 비염의 예방 및 치료를 위해 아미카신 및 이의약제학적으로 허용가능한 염과, 베타-글루칸을 유효성분을포함하는 비강 분무용 조성물
AU2002236587A1 (en) Compositions for adhesion prevention
WO2002074287A3 (en) Antibacterial compositions containing of oxapenem-3-carboxylic acids and antibiotics
DE60202299D1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1320355

Country of ref document: EP